secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2022-05-11T23:59:59+00:00
Accession:  0001157523-22-000612
Event type: earnings
Sentiment:  neutral
Materiality: 0.40
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise Therapeutics reports Q1 2022 net loss of $14.7M; cash at $265.8M
-------------------------------------------------------------------------

- Net loss of $14.7M ($0.30 per share) vs. $12.7M in the prior quarter.
- Cash, equivalents and marketable securities of $265.8M; expected to fund operations through 2024.
- Completed enrollment of ARCH open-label study of EDG-5506 in BMD; Phase 2 trials planned for 2022.
- R&D expenses $11.1M, up $2.0M from prior quarter; G&A flat at $3.7M.
- Advanced preclinical EDG-002 program targeting hypertrophic cardiomyopathy; IND-enabling studies in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000115752322000612/0001157523-22-000612-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000115752322000612/a52714442.htm
  HTML page:      https://secwatch.observer/filing/0001157523-22-000612

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer